Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients

Background: Public health advisories have warned that the use of atypical antipsychotic medications increases the risk of death among elderly patients. We assessed the short-term mortality in a population-based cohort of elderly people in British Columbia who were prescribed conventional and atypical antipsychotic medications. Methods: We used linked health care utilization data of all BC residents to identify a cohort of people aged 65 years and older who began taking antipsychotic medications between January 1996 and December 2004 and were free of cancer. We compared the 180-day all-cause mortality between residents taking conventional antipsychotic medications and those taking atypical antipsychotic medications. Results: Of 37 241 elderly people in the study cohort, 12 882 were prescribed a conventional antipsychotic medication and 24 359 an atypical formulation. Within the first 180 days of use, 1822 patients (14.1%) in the conventional drug group died, compared with 2337 (9.6%) in the atypical drug group (mortality ratio 1.47, 95% confidence interval [CI] 1.39–1.56). Multivariable adjustment resulted in a 180-day mortality ratio of 1.32 (1.23–1.42). In comparison with risperidone, haloperidol was associated with the greatest increase in mortality (mortality ratio 2.14, 95% CI 1.86–2.45) and loxapine the lowest (mortality ratio 1.29, 95% CI 1.19–1.40). The greatest increase in mortality occurred among people taking higher (above median) doses of conventional antipsychotic medications (mortality ratio 1.67, 95% CI 1.50–1.86) and during the first 40 days after the start of drug therapy (mortality ratio 1.60, 95% CI 1.42–1.80). Results were confirmed in propensity score analyses and instrumental variable estimation, minimizing residual confounding. Interpretation: Among elderly patients, the risk of death associated with conventional antipsychotic medications is comparable to and possibly greater than the risk of death associated with atypical antipsychotic medications. Until further evidence is available, physicians should consider all antipsychotic medications to be equally risky in elderly patients.

[1]  M Alan Brookhart,et al.  Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. , 2006, Arthritis and rheumatism.

[2]  M Alan Brookhart,et al.  Evaluating Short-Term Drug Effects Using a Physician-Specific Prescribing Preference as an Instrumental Variable , 2006, Epidemiology.

[3]  S. Schneeweiss.  Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics , 2006, Pharmacoepidemiology and drug safety.

[4]  L. Hirsch.  Competing interests: none declared. , 2006 .

[5]  J. Avorn,et al.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications. , 2005, The New England journal of medicine.

[6]  Lon S Schneider,et al.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. , 2005, JAMA.

[7]  Donna Spiegelman,et al.  Easy SAS calculations for risk or prevalence ratios and differences. , 2005, American journal of epidemiology.

[8]  Jalpa A Doshi,et al.  The quality of antipsychotic drug prescribing in nursing homes. , 2005, Archives of internal medicine.

[9]  B. Kuehn.  FDA warns antipsychotic drugs may be risky for elderly. , 2005, JAMA.

[10]  J. Avorn,et al.  A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.

[11]  B. Lawlor.  Behavioral and psychological symptoms in dementia: the role of atypical antipsychotics. , 2004, The Journal of clinical psychiatry.

[12]  G. Alexopoulos,et al.  Commentary: Expert Consensus Guidelines for Using Antipsychotic Agents in Older Patients , 2004 .

[13]  G. Alexopoulos,et al.  Using antipsychotic agents in older patients. , 2004, The Journal of clinical psychiatry.

[14]  W. Ray,et al.  Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.

[15]  M Soledad Cepeda,et al.  Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. , 2003, American journal of epidemiology.

[16]  Paul R Rosenbaum,et al.  Rare Outcomes, Common Treatments: Analytic Strategies Using Propensity Scores , 2002, Annals of Internal Medicine.

[17]  H. Pincus,et al.  Comparison of adult and geriatric psychiatric practice patterns: findings from the American Psychiatric Association's Practice Research Network. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[18]  G. Remington,et al.  How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience. , 2002, Clinical therapeutics.

[19]  R. Weizman,et al.  Would a Switch From Typical Antipsychotics to Risperidone Be Beneficial for Elderly Schizophrenic Patients? A Naturalistic, Long-Term, Retrospective, Comparative Study , 2002, Journal of clinical psychopharmacology.

[20]  Christian R. Dolder,et al.  Antipsychotic medication adherence: is there a difference between typical and atypical agents? , 2002, The American journal of psychiatry.

[21]  M Maclure,et al.  Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. , 2001, American journal of epidemiology.

[22]  B. Winblad,et al.  Psychotropic drug use in elderly people with and without dementia , 2001, International journal of geriatric psychiatry.

[23]  P. Tariot.  The older patient: the ongoing challenge of efficacy and tolerability. , 1999, The Journal of clinical psychiatry.

[24]  S. Pariser,et al.  Atypical Antipsychotics in Older Adults , 1999, Pharmacotherapy.

[25]  P. Schuster,et al.  Comorbidity in primary care: presentation and consequences. , 1999, The Journal of clinical psychiatry.

[26]  R. Tandon,et al.  The efficacy, safety, and tolerability of antipsychotics in the elderly. , 1999, The Journal of clinical psychiatry.

[27]  B J McNeil,et al.  Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. , 1994, JAMA.

[28]  J. Jollis,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. , 1993, Journal of clinical epidemiology.

[29]  Joshua D. Angrist,et al.  Identification of Causal Effects Using Instrumental Variables , 1993 .

[30]  J M Robins,et al.  Confounding and misclassification. , 1985, American journal of epidemiology.

[31]  C. Shamoian.  Clinical Geriatric Psychopharmacology , 1985 .

[32]  H. Pitkow,et al.  Basic and Clinical Pharmacology , 1983 .

[33]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .